Pirfenidone Tablet, Coated
Product Images NDC 71335-2944

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 71335-2944). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352944)

This text provides information about a medication called Pirfenidone, which comes in the form of film-coated tablets containing 267 mg. The recommended storage temperature is between 25°C to 30°C. The dosage and administration details can be accessed by scanning the package insert QR code. The medication is available in packs of 270 tablets (3 bottles of 90 tablets each) and is relabeled by Bryant Ranch Prepack, Inc. It is manufactured by Alembic Pharmaceuticals.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

This information is a comparison between patients taking Pirfenidone and Placebo in terms of the absolute change in forced vital capacity (%FVC) from baseline to week 52. The data shows that the percentage of patients with worsening %FVC was lower in the Pirfenidone group compared to the Placebo group, indicating that Pirfenidone may be more effective in slowing down the decline in lung function.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

Mean Change in Forced Vital Capacity (FVC) in milliliters (mL) over a period of 52 weeks. The data compares the impact of Pirfenidone with a sample size of 278 individuals to a Placebo group with 277 individuals. The graph shows the decrease in FVC over time, with the Pirfenidone group showing improvement in FVC compared to the Placebo group.*

FDA Label Image

Figure 3 (Pirfenidone Figure3)

This text provides survival data for patients in a clinical trial comparing the drug Pirfenidone with a placebo. The percentage of patients alive over time is displayed graphically. The hazard ratio for Pirfenidone compared to placebo is reported as 0.75 with a 95% confidence interval of 0.51 to 1.11. The number of patients at risk at different time points is also provided.*

FDA Label Image

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)

This text provides a dosing schedule for Pirfenidone Tablets with a dosage of 267 mg. The schedule details the number of tablets to be taken in the morning, afternoon, and evening for each week. For days 1 to 7, the total number of pills to be taken each day is 3, increasing to 6 pills a day for days 8 to 14, and finally, 9 pills a day starting from day 15 onward.*

FDA Label Image

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)

This is a dosage schedule for Pirfenidone tablets of 801 mg. It shows the number of tablets to be taken in the morning, afternoon, and evening each day starting from day 15 onwards. The total number of pills per day is 3.*

FDA Label Image

Pirfenidone (Pirfenidone Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.